AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III

Benzinga · 2d ago

Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial

Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer